Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Sela

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Rejuvenation Research|April 13, 2006
Immunomodulatory vaccines against autoimmune diseasesMichael Sela
Journal of Molecular Recognition : JMR|January 21, 2004
Immunomodulation by the copolymer glatiramer acetateRuth Arnon, Michael Sela
Proceedings of the National Academy of Sciences of the United States of America|August 17, 2004
Therapeutic vaccines in autoimmunityMichael Sela, Edna Mozes
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2015
Cancer Immunotherapy: More Is (Much) BetterYosef Yarden, Michael Sela
Methods in Molecular Biology (Clifton, N.J.)|June 15, 2015
Aptamer Targeting the ERBB2 Receptor Tyrosine Kinase for Applications in Tumor TherapyGeorg Mahlknecht, Michael Sela, Yosef Yarden
Drug Discovery Today|July 12, 2002
Therapeutic vaccines: realities of today and hopes for the futureMichael Sela, Ruth Arnon, Bilha Schechter
Physiology (Bethesda, Md.)|May 1, 2010
Roles for growth factors in cancer progressionEsther Witsch, Michael Sela, Yosef Yarden
Proceedings of the National Academy of Sciences of the United States of America|January 29, 2005
Down-regulation of myasthenogenic T cell responses by a dual altered peptide ligand via CD4+CD25+-regulated events leading to apoptosisHava Ben-David, Michael Sela, Edna Mozes
Proceedings of the National Academy of Sciences of the United States of America|July 15, 2005
Suppression of myasthenogenic responses of a T cell line by a dual altered peptide ligand by induction of CD4+CD25+ regulatory cellsBadiga Venkata Aruna, Michael Sela, Edna Mozes
Proceedings of the National Academy of Sciences of the United States of America|May 14, 2003
A dual altered peptide ligand down-regulates myasthenogenic T cell responses by up-regulating CD25- and CTLA-4-expressing CD4+ T cellsMiri Paas-Rozner, Michael Sela, Edna Mozes
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Rejuvenation Research|April 13, 2006
Immunomodulatory vaccines against autoimmune diseasesMichael Sela
Journal of Molecular Recognition : JMR|January 21, 2004
Immunomodulation by the copolymer glatiramer acetateRuth Arnon, Michael Sela
Proceedings of the National Academy of Sciences of the United States of America|August 17, 2004
Therapeutic vaccines in autoimmunityMichael Sela, Edna Mozes
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2015
Cancer Immunotherapy: More Is (Much) BetterYosef Yarden, Michael Sela
Methods in Molecular Biology (Clifton, N.J.)|June 15, 2015
Aptamer Targeting the ERBB2 Receptor Tyrosine Kinase for Applications in Tumor TherapyGeorg Mahlknecht, Michael Sela, Yosef Yarden
Drug Discovery Today|July 12, 2002
Therapeutic vaccines: realities of today and hopes for the futureMichael Sela, Ruth Arnon, Bilha Schechter
Physiology (Bethesda, Md.)|May 1, 2010
Roles for growth factors in cancer progressionEsther Witsch, Michael Sela, Yosef Yarden
Proceedings of the National Academy of Sciences of the United States of America|January 29, 2005
Down-regulation of myasthenogenic T cell responses by a dual altered peptide ligand via CD4+CD25+-regulated events leading to apoptosisHava Ben-David, Michael Sela, Edna Mozes
Proceedings of the National Academy of Sciences of the United States of America|July 15, 2005
Suppression of myasthenogenic responses of a T cell line by a dual altered peptide ligand by induction of CD4+CD25+ regulatory cellsBadiga Venkata Aruna, Michael Sela, Edna Mozes
Proceedings of the National Academy of Sciences of the United States of America|May 14, 2003
A dual altered peptide ligand down-regulates myasthenogenic T cell responses by up-regulating CD25- and CTLA-4-expressing CD4+ T cellsMiri Paas-Rozner, Michael Sela, Edna Mozes
Pageof 5